Efficacy of celecoxib in the treatment of refractory lymphatic anomalies
10.3760/cma.j.cn114453-20220522-00155
- VernacularTitle:塞来昔布治疗儿童难治性淋巴管畸形的临床效果
- Author:
Yuan WANG
1
;
Tao HAN
;
Jie CUI
;
Weimin SHEN
Author Information
1. 南京医科大学附属儿童医院烧伤整形外科，南京 210008
- Keywords:
Lymphatic abnormalities;
Celecoxib;
Efficacy
- From:
Chinese Journal of Plastic Surgery
2023;39(1):60-64
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To determine the efficacy of treatment of refractory lymphatic anomalies with celecoxib.Methods:The authors retrospectively analyzed the characteristics, treatments and complications of patients treated with celecoxib in Children’s Hospital of Nanjing Medical University from September 2020 to January 2022. Treatment was started after poor response to other method or pain, which consisted of a continuous dosing schedule of oral celecoxib at 5 mg.kg -1.d -1, twice daily, for 6 months. Efficacy and safety were evaluated according to radiologic assessment, quality of life and incidence of adverse events. The efficacy was divided into complete response, partial response, stablizing response and non-responsive. SPSS 21.0 was used for data analysis. The data were expressed by M( Q1, Q3). Wilcoxon test was used to compare the lesion volume and PedsQL score before and after treatment. P<0.05 indicated that the difference was statistically significant. Results:A total of 12 patients with lymphatic malformation were enrolled, including 7 males and 5 females aging from 1 year and 5 months to 9 years and 9 months. Eight patients kept stable disease while two patients achieve partial response and two patients presented progressive disease. The median volume of lesions before treatment was 59.13(38.19, 107.15) cm 3 and was 66.08(37.37, 119.98) cm 3 after the treatment. There was no significant difference in volume changes ( Z=0.40, P=0.686). The PedsQL score was 30.5 (29.0, 32.0) before and 29.0(28.0, 30.0) after the treatment. There was no significant difference in the change of PedsQL score( Z=1.73, P=0.084). The side effects occurred in one patient as poor sleeping. Conclusion:Celecoxib can not reduce the lesion but may be helpful for improving life quality in lymphatic malformations.
